What do systematic reviews say?

Methotrexate vs other DMARDs

• Methotrexate for psoriatic arthritis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 35 participants
  Very low

Methotrexate vs other DMARDs

It is very uncertain whether methotrexate changes withdrawals due to adverse events (ciclosporin A) assessed by number… compared with other DMARDs (very low certainty).

• Methotrexate for psoriatic arthritis 2019 · Cochrane Headline outcomes only
  RR 1.26 [0.33, 4.82]
  1 study · 35 participants
  Very low

First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors vs first‐line ciclosporin and/or antithymocyte or antilymphocyte globulin

First‐line allogeneic hematopoietic stem cell transplantation of… showed no clear difference in overall mortality compared with first‐line ciclosporin and/or antithymocyte or antilymphocyte globulin (low certainty).

• First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors compared with first‐line… 2013 · Cochrane Headline outcomes only
  HR 0.95 [0.45, 1.91]
  3 studies · 203 participants
  Low

First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors vs first‐line ciclosporin and/or antithymocyte or antilymphocyte globulin

• First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors compared with first‐line… 2013 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 54 participants
  Very low

First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors vs first‐line ciclosporin and/or antithymocyte or antilymphocyte globulin

• First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors compared with first‐line… 2013 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors vs first‐line ciclosporin and/or antithymocyte or antilymphocyte globulin

• First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors compared with first‐line… 2013 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 54 participants
  Very low

First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors vs first‐line ciclosporin and/or antithymocyte or antilymphocyte globulin

• First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors compared with first‐line… 2013 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 35 participants
  Very low

First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors vs first‐line ciclosporin and/or antithymocyte or antilymphocyte globulin

• First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors compared with first‐line… 2013 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 52 participants
  Very low

First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors vs first‐line ciclosporin and/or antithymocyte or antilymphocyte globulin

First‐line allogeneic hematopoietic stem cell transplantation of… showed no clear difference in secondary clonal disease or malignancies compared with first‐line ciclosporin and/or antithymocyte or antilymphocyte globulin (low certainty).

• First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors compared with first‐line… 2013 · Cochrane Headline outcomes only
  Peto OR 0.54 [0.07, 4]
  2 studies · 170 participants
  Low

Tacrolimus vs ciclosporin

It is very uncertain whether tacrolimus changes clinical remission compared with ciclosporin (very low certainty).

• Tacrolimus (FK506) for induction of remission in corticosteroid‐refractory ulcerative colitis 2022 · Cochrane Headline outcomes only
  RR 1.52 [0.92, 2.5]
  1 study · 113 participants
  Very low

Tacrolimus vs ciclosporin

It is very uncertain whether tacrolimus changes clinical improvement compared with ciclosporin (very low certainty).

• Tacrolimus (FK506) for induction of remission in corticosteroid‐refractory ulcerative colitis 2022 · Cochrane Headline outcomes only
  RR 0.9 [0.7, 1.16]
  1 study · 113 participants
  Very low

Tacrolimus vs ciclosporin

The review found no eligible studies for this question.

• Tacrolimus (FK506) for induction of remission in corticosteroid‐refractory ulcerative colitis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Tacrolimus vs ciclosporin

The review found no eligible studies for this question.

• Tacrolimus (FK506) for induction of remission in corticosteroid‐refractory ulcerative colitis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Tacrolimus 0.1% vs ciclosporin

It is very uncertain whether tacrolimus 0.1% changes adverse effects compared with ciclosporin (very low certainty).

• Topical tacrolimus for atopic dermatitis 2015 · Cochrane Headline outcomes only
  RR 1 [0.31, 3.28]
  1 study · 30 participants
  Very low